Therapeutic strategies in pulmonary arterial hypertension

Carmine Dario Vizza, Roberto Badagliacca, Roberto Poscia, Mario Mezzapesa, Martina Nocioni, Francesco Fedele

Research output: Contribution to journalArticlepeer-review


Pulmonary arterial hypertension (PAH) is a serious and life-threatening condition for which the prognosis remains poor. Treatment options include endothelial receptor antagonists, phosphodiesterase (PDE5) inhibitors and prostanoids. Despite all demonstrating good short-term efficacy, none of the currently available drug therapies are curative. Treatment with prostanoids is complex and requires careful monitoring and management through a specialist centre. Furthermore, clinical efficacy is dependent on adequate up-titration of the drug. Treatment should be individualised and modified according to clinical response, with the addition of other therapies if required. The importance of monitoring and modifying therapeutic regimes is discussed. There appears to be reluctance among patients and physicians to employ prostanoid therapy, though an aggressive first-line therapy may be appropriate in advanced cases.

Original languageEnglish
Pages (from-to)198-203
Number of pages6
JournalEuropean Cardiology
Issue number3
Publication statusPublished - 2012


  • Endothelin receptor antagonists
  • Phosphodiesterase inhibitors
  • Prostanoids
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Therapeutic strategies in pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this